Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT04965831
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.

Study Details

This is a phase II study aimed to assess the efficacy and safety of furmonertinib, a third generation EGFR TKI, as perioperation therapy in stage IIIA-IIIB (N1-N2) resectable NSCLC patients.

Key Dates

Start date
Aug 1, 2021
Status verified
Jun 2021
Primary completion
Mar 1, 2023
Completion
May 1, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib
    Furmonertinib as perioperation therapy

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Approximately 8 weeks following the first dose of study drug ]

Central Contacts

Related Studies